Treatment Patterns And Outcomes In Patients Treated With Benefix Or Refacto/Refacto AF - A Swedish Cohort Study
30 gennaio 2019 aggiornato da: Pfizer
TREATMENT PATTERNS AND OUTCOMES IN PATIENTS TREATED WITH BENEFIX OR REFACTO/REFACTO AF - A SWEDISH COHORT STUDY
The overall aim of the study is to describe demographic and clinical characteristics, treatment patterns and outcomes, in the populations of hemophilia patients treated with BeneFIX and ReFacto/ReFacto AF in Sweden
Panoramica dello studio
Stato
Completato
Condizioni
Descrizione dettagliata
The overall aim of the study is to describe demographic and clinical characteristics, treatment patterns and outcomes, as well as the related direct treatment costs in the populations of hemophilia patients treated with BeneFIX and ReFacto/ReFacto AF, and in subgroups (e.g. level of severity) at the MHC in Sweden.
The study population will consist of all patients diagnosed with haemophilia (D66.9 (haemophilia A) D67.9 (haemophilia B) in International Statistical Classification of Diseases and Related Health Problems (ICD-10) that have been registered in the MHR since 1977 and that have had at least one registered prescription of BeneFIX or ReFacto/ReFacto AF in the MHR since market authorization of the respective product (Benefix August 27 1997, ReFacto April 13 1999, ReFacto AF July 1 2009). Diseased individuals are included. Information on drugs picked up at the pharmacy is available in the Prescribed Drug Register from 2005.
Tipo di studio
Osservativo
Iscrizione (Effettivo)
86
Criteri di partecipazione
I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.
Criteri di ammissibilità
Età idonea allo studio
- Bambino
- Adulto
- Adulto più anziano
Accetta volontari sani
No
Metodo di campionamento
Campione di probabilità
Popolazione di studio
The study population will consist of all patients diagnosed with hemophilia (D66.9 (hemophilia A) D67.9 (hemophilia B) in International Statistical Classification of Diseases and Related Health Problems (ICD-10) that have been registered in the Malmö Hemophilia Register since 1977 and that have had at least one registered prescription of BeneFIX or ReFacto/ReFacto AF in the MHR since market authorization of the respective product (Benefix August 27 1997, ReFacto April 13 1999, ReFacto AF July 1 2009).
Diseased individuals are included.
Descrizione
Inclusion Criteria:
- The study population will consist of all patients diagnosed with hemophilia (D66.9 (hemophilia A) D67.9 (hemophilia B) in International Statistical Classification of Diseases and Related Health Problems (ICD-10) that have been registered in the Malmö Hemophilia Register since 1977 and that have had at least one registered prescription of BeneFIX or ReFacto/ReFacto AF in the MHR since market authorization of the respective product
Exclusion Criteria:
- No exclusion criteria in this study
Piano di studio
Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.
Come è strutturato lo studio?
Dettagli di progettazione
Coorti e interventi
Gruppo / Coorte |
|---|
|
Patients with Haemophilia A
Patients in The MHR diagnosed with Haemophilia A
|
|
Patients with Haemophilia B
Patients in The MHR diagnosed with Haemophilia B
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Age of Participants at Disease Diagnosis
Lasso di tempo: At disease diagnosis within 11 years before the study start date (Day 1)
|
At disease diagnosis within 11 years before the study start date (Day 1)
|
|
|
Age of Participants at Start of Treatment With Benefix or Refacto
Lasso di tempo: At start of treatment with Benefix/Refacto within 11 years before the study start date (Day 1)
|
At start of treatment with Benefix/Refacto within 11 years before the study start date (Day 1)
|
|
|
Age of Participants at Start of Replacement Treatment
Lasso di tempo: At start of replacement treatment within 11 years before the study start date (Day 1)
|
Participants diagnosed with coagulation disorders received intravenous replacement treatment of the missing coagulation factor.
Replacement treatment could be given prophylactically or to stop the bleed and/or to stop it from becoming more severe.
|
At start of replacement treatment within 11 years before the study start date (Day 1)
|
|
Average Prescribed Dose Per Infusion for Factor VIII and Factor IX Concentrates
Lasso di tempo: For the duration of 11 years before the study start date (Day 1)
|
Participants diagnosed with coagulation disorders received intravenous replacement treatment of the missing coagulation factor (Factor VIII or IX).
Data was measured in international units (IU) for factor VIII and factor IX concentrates.
|
For the duration of 11 years before the study start date (Day 1)
|
|
Average Prescribed Dose Per Kilogram Bodyweight for Factor VIII and Factor IX Concentrates
Lasso di tempo: For the duration of 11 years before the study start date (Day 1)
|
The average dose per kilogram body weight of factor VIII and IX was defined as a set of two derived variables from the MHR based on information on prescribed replacement treatment (Benefix or Refacto/Refacto AF): prescribed dose per infusion divided by registered body weight (all participants) and prescribed dose per week (prescribed dose per infusion multiplied by registered number of infusions per week) divided by registered body weight (only participants on prophylaxis).
|
For the duration of 11 years before the study start date (Day 1)
|
|
Percentage of Participants on Prophylactic Treatment
Lasso di tempo: For the duration of 11 years before the study start date (Day 1)
|
Prophylactic treatment was defined as administration of drug regularly to reduce the insufficiency of coagulation factor to prevent bleeding to occur.
|
For the duration of 11 years before the study start date (Day 1)
|
|
Average Prescribed Frequency of Infusions Per Week Dispensed for Haemophilia A or B Participants With Prophylaxis
Lasso di tempo: For the duration of 11 years before the study start date (Day 1)
|
For the duration of 11 years before the study start date (Day 1)
|
|
|
Average Prescribed Annual Dose of Factor VIII and IX Concentrates for Participants on Prophylaxis
Lasso di tempo: For the duration of 11 years before the study start date (Day 1)
|
Participants diagnosed with coagulation disorders received intravenous replacement treatment of the missing coagulation factor (Factor VIII or IX).
Prescribed annual dose of factor concentrate was derived from the MHR registration of prescribed annual dose of factor concentrate.
|
For the duration of 11 years before the study start date (Day 1)
|
|
Average Prescribed Annual Dose of Factor VIII and IX Concentrates Per Kilogram Bodyweight for Participants on Prophylaxis
Lasso di tempo: For the duration of 11 years before the study start date (Day 1)
|
Participants diagnosed with coagulation disorders received intravenous replacement treatment of the missing coagulation factor (Factor VIII or IX).
Prescribed annual dose of factor concentrate per kilogram body weight was derived from the MHR registration of prescribed annual dose of factor concentrate and the registered body weight.
|
For the duration of 11 years before the study start date (Day 1)
|
|
Average Annual Registered Consumption of Factor VIII and IX Concentrates
Lasso di tempo: For the duration of 11 years before the study start date (Day 1)
|
Participants diagnosed with coagulation disorders received intravenous replacement treatment of the missing coagulation factor (Factor VIII or IX).
Average annual registered consumption of factor VIII and IX concentrates was defined as MHR registered participant's reports on factor concentrate consumption during calendar year.
|
For the duration of 11 years before the study start date (Day 1)
|
|
Number of Participants With Consumption of Factor VIII, Factor IX, Factor rVIIa and/or aPCC Concentrate
Lasso di tempo: For the duration of 11 years before the study start date (Day 1)
|
Participants who develop inhibitors to factor VIII or IX concentrates were treated with bypassing agents in the form of activated prothrombin complex concentrate (aPCC) which was measured in units (U) and/or recombinant factor VIIa (rFVIIa) measured in micrograms (mcg).
|
For the duration of 11 years before the study start date (Day 1)
|
|
Percentage of Time on Refacto or Benefix
Lasso di tempo: For the duration of 11 years before the study start date (Day 1)
|
Percentage of time (in days) on Refacto/Refacto AF or Benefix was calculated as total number of days when participant was prescribed Refacto/Refacto AF or Benefix over the total number of days on any replacement treatment.
Total number of days on any replacement treatment was derived from date of start of replacement treatment according to MHR and August 31, 2015 or date of death, whichever was earliest.
|
For the duration of 11 years before the study start date (Day 1)
|
|
Average Use of Factor Concentrate Per Surgery Event at Hospital for Invasive Procedures
Lasso di tempo: For the duration of 11 years before the study start date (Day 1)
|
For the duration of 11 years before the study start date (Day 1)
|
|
|
Average Factor Concentrate Use at Hospital for Invasive Procedures
Lasso di tempo: For the duration of 11 years before the study start date (Day 1)
|
Average factor concentrate use was calculated as percentage of total annual use of factor concentrates (in IU) at hospital for invasive procedures.
|
For the duration of 11 years before the study start date (Day 1)
|
|
Average Annual Number of Filled Prescriptions of Factor Concentrate
Lasso di tempo: For a duration of 3 years (for up to 11 years before the study start Day 1)
|
Data at end of every year was based on the number of filled prescriptions during the last 3 years.
|
For a duration of 3 years (for up to 11 years before the study start Day 1)
|
|
Average Annual Number of Dispensed Units of Factor Concentrate
Lasso di tempo: For a duration of 3 years (for up to 11 years before the study start Day 1)
|
To assess annual consumption of factor concentrates, calculations were based on prescription date as start of use and the day before the next prescription as the last date of use of the factor concentrates retrieved.
The annual number of dispensed units of factor concentrate were then summed up of all dispensed units of factor concentrate with periods within the calendar year plus estimates of average daily use periods extending over two years.
Data at end of every year was based on the number of dispensed units of factor concentrate during the last 3 years.
|
For a duration of 3 years (for up to 11 years before the study start Day 1)
|
|
Average Number of Units of Benefix or Refacto
Lasso di tempo: For the duration of 11 years before the study start date (Day 1)
|
Data from the National Board of Health and Welfare (NBHW) had information on all filled prescriptions from July 1, 2005-last date of observation (August 31, 2015).
Derived variable calculated as total number of units of filled prescriptions of Refacto/Refacto AF and Benefix over the total units of all factor VIII concentrates and factor IX concentrates, respectively.
Total number of units were derived from the date of start of NBHW to last available observation or date of death, whichever was earliest.
|
For the duration of 11 years before the study start date (Day 1)
|
|
Total Number of Bleeds
Lasso di tempo: For the duration of 11 years before the study start date (Day 1)
|
For the duration of 11 years before the study start date (Day 1)
|
|
|
Number of Joint Bleed, Muscle Bleeds and Other Bleed Events in Participants
Lasso di tempo: For the duration of 11 years before the study start date (Day 1)
|
Joint bleeds included traumatic and spontaneous joint bleeds, muscle bleeds included traumatic and spontaneous soft tissue bleeds and other bleed events included intracranial bleed, gastrointestinal bleed and urinary tract bleed.
|
For the duration of 11 years before the study start date (Day 1)
|
|
Gilbert Joint Score
Lasso di tempo: Data analyzed on study start Day 1 for the duration of 4 years (2005 to 2009)
|
Gilbert joint score was an instrument to measure joint health in the domain of body structure and function (i.e.
impairment), of the joints most commonly affected by bleeding in haemophilia - knees, ankles, elbows.
Total score ranged from 0-100, evaluating ankle, knee and elbow, where "0" indicated normal joint function, "100" indicated worst joint function, where higher values indicated more impairment in joints.
|
Data analyzed on study start Day 1 for the duration of 4 years (2005 to 2009)
|
|
Haemophilia Joint Health Score
Lasso di tempo: Data analyzed on study start Day 1 for the duration of 6 years (2009 to 2015)
|
Haemophilia Joint Health Score (HJHS) was used to assess joint damage in participants with haemophilia.
Total score ranges from 0 to 124, where, 0 indicates normal function, and 124 indicates worst joint function, higher values indicated more damage in joints.
|
Data analyzed on study start Day 1 for the duration of 6 years (2009 to 2015)
|
|
Percentage of Participants With Surgeries
Lasso di tempo: For the duration of 11 years before the study start date (Day 1)
|
Percentage of participants who had any type of surgery (arthrodesis, surgery on foot, nose, elbow, hand or shoulder, surgery on hip, surgery on knee, tooth extraction, venous port or any other) during the data observation period were reported.
|
For the duration of 11 years before the study start date (Day 1)
|
|
Average Relative Dose Intensity of Factor Concentrate Dispensed for Haemophilia A or B Participants on Prophylaxis Based on Dispensed Volume of Units
Lasso di tempo: For the duration of 11 years before the study start date (Day 1)
|
Relative dose intensity based on dispensed volume of units was calculated using annual dispensed volume of factor concentrate per participant divided by annual prescribed dose per participant.
Data was analysed for 2 categories separately: children/adolescents and adults.
|
For the duration of 11 years before the study start date (Day 1)
|
|
Average Cost of Replacement Treatment (Benefix or Refacto/Refacto AF) Related to Bleed Event
Lasso di tempo: For the duration of 11 years before the study start date (Day 1)
|
For the duration of 11 years before the study start date (Day 1)
|
Misure di risultato secondarie
Misura del risultato |
Lasso di tempo |
|---|---|
|
Average Annual Cost of Prescribed Factor Concentrate and Dispensed Replacement Treatment
Lasso di tempo: For the duration of 11 years before the study start date (Day 1)
|
For the duration of 11 years before the study start date (Day 1)
|
|
Average Cost of Replacement Treatment Related to Invasive Procedures
Lasso di tempo: For the duration of 11 years before the study start date (Day 1)
|
For the duration of 11 years before the study start date (Day 1)
|
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Average Annual Cost of Replacement Treatment Related to Invasive Procedures
Lasso di tempo: Data analyzed on study start Day 1 for Year 1 (2005) and Year 7 (2011)
|
Data analyzed on study start Day 1 for Year 1 (2005) and Year 7 (2011)
|
|
|
Average Cost for Replacement Treatment Related to Invasive Procedures
Lasso di tempo: Data analyzed on study start Day 1 for Year 1 (2005) and Year 7 (2011)
|
The average cost for replacement treatment related to invasive procedures was derived from the percentage of total costs for dispensed replacement therapy and calculated as: cost of factor concentrate used for invasive procedures/ total cost of factor concentrate.
|
Data analyzed on study start Day 1 for Year 1 (2005) and Year 7 (2011)
|
Collaboratori e investigatori
Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.
Sponsor
Pubblicazioni e link utili
La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.
Studiare le date dei record
Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.
Studia le date principali
Inizio studio (Effettivo)
11 gennaio 2016
Completamento primario (Effettivo)
31 dicembre 2017
Completamento dello studio (Effettivo)
31 dicembre 2017
Date di iscrizione allo studio
Primo inviato
16 dicembre 2015
Primo inviato che soddisfa i criteri di controllo qualità
11 aprile 2016
Primo Inserito (Stima)
15 aprile 2016
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
3 maggio 2019
Ultimo aggiornamento inviato che soddisfa i criteri QC
30 gennaio 2019
Ultimo verificato
1 gennaio 2019
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- B1821054
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
NO
Descrizione del piano IPD
Pfizer will provide access to individual de-identified participant data and related study documents (e.g.
protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions.
Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .